Adolor Corp.'s beleaguered shares got a 20 percent boost on Wednesday after the company announced a $265 million deal with Pfizer Inc. for the delta opioid agonists ADL5859 and ADL5747. (BioWorld Today)
Adolor Corp.'s beleaguered shares got a 20 percent boost on Wednesday after the company announced a $265 million deal with Pfizer Inc. for the delta opioid agonists ADL5859 and ADL5747. (BioWorld Today)
Amid a flurry of stem cell news, Fate Therapeutics raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. (BioWorld Today)
Amid a flurry of stem cell news, Fate Therapeutics raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. (BioWorld Today)
